S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,786.41 +1.39%
Next Bullish Trade
Sign in
AQST

Aquestive Therapeutics, Inc. AQST

$4.12 +0.18 (+4.57%)
Neutral · -0.33σ
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · AQST

Momentum reads · latest daily bar
Last
$4.12
+0.18 (+4.57%)
Mkt cap
$517M
Healthcare
RSI(14)
46.8
neutral
Stochastic %K
24.6
neutral
MFI(14)
34.1
neutral
ADX(14)
12.9
weak trend

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $0.0B $-0.0B $-0.0B $-0.0B -55.8% -29.1%
2025-12-31 $0.0B $-0.0B $-0.0B $-0.0B -244.8% -221.6%
2025-09-30 $0.0B $-0.0B $-0.0B $-0.0B -120.6% -89.6%
2025-06-30 $0.0B $-0.0B $-0.0B $-0.0B -135.4% -113.6%
2025-03-31 $0.0B $-0.0B $-0.0B $-0.0B -263.0% -222.1%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare AQST vs peers

Line AQST up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing AQST no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with AQST

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 0 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

No earnings history available.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
AQST ★ $1B — -9.2 10.3 -8.1 -15.0 63.5% 65.7% — -4.97%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0% —
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 35.77%

HolderShares% out
Bratton Capital Management, LP 9,810,958 7.82%
Blackrock Inc. 7,509,071 5.98%
RTW Investments LP 7,426,471 5.92%
Vanguard Capital Management LLC 4,443,698 3.54%
Federated Hermes, Inc. 2,940,339 2.34%
Balyasny Asset Management LP 2,900,570 2.31%
State Street Corporation 2,546,191 2.03%
Samsara BioCapital, LLC 2,500,000 1.99%
Geode Capital Management, LLC 2,408,191 1.92%
Bank of America Corporation 2,405,050 1.92%

Insider activity · 90d

8 buys / 3 sells · ratio 2.67 · Finnhub

  • Krop Julie M 0
  • Krop Julie SELL 0 @ $5.02
  • Krop Julie M 25,000 @ $0.71
  • Barber Daniel SELL 635,574 @ $4.16
  • Krop Julie BUY 50,500
  • Jenkins Abigail L. BUY 50,500
  • Cochran John BUY 50,500
  • Taglietti Marco BUY 50,500
  • BROWN GREGORY B BUY 50,500
  • MORRIS TIMOTHY E BUY 50,500

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$6.0
Mean
$8.88889
High
$11.0
Analysts
9
Recommendation distribution · period 2026-07-01
4
10
1
Revision trend (2026-04-01 → 2026-07-01): net 14 → 14 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-07-17 PRIMARY DOCUMENT view ·
4 2026-06-24 PRIMARY DOCUMENT view ·
4 2026-06-16 PRIMARY DOCUMENT view ·
4 2026-06-12 PRIMARY DOCUMENT view ·
4 2026-06-12 PRIMARY DOCUMENT view ·
4 2026-06-12 PRIMARY DOCUMENT view ·
4 2026-06-12 PRIMARY DOCUMENT view ·
4 2026-06-12 PRIMARY DOCUMENT view ·
4 2026-06-12 PRIMARY DOCUMENT view ·
8-K 2026-06-10 8-K view ·
4 2026-06-09 PRIMARY DOCUMENT view ·
4 2026-05-19 PRIMARY DOCUMENT view ·
4 2026-05-18 PRIMARY DOCUMENT view ·
4 2026-05-18 PRIMARY DOCUMENT view ·
10-Q 2026-05-13 10-Q view ·
8-K 2026-05-13 8-K view ·
4 2026-05-11 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
4 2026-05-07 PRIMARY DOCUMENT view ·
DEF 14A 2026-04-24 DEF 14A view ·
4 2026-04-13 PRIMARY DOCUMENT view ·
4 2026-04-13 PRIMARY DOCUMENT view ·
4 2026-04-13 PRIMARY DOCUMENT view ·
4 2026-04-13 PRIMARY DOCUMENT view ·
4 2026-04-13 PRIMARY DOCUMENT view ·
4 2026-04-13 PRIMARY DOCUMENT view ·
8-K 2026-03-30 8-K view ·
8-K 2026-03-20 8-K view ·
4 2026-03-11 PRIMARY DOCUMENT view ·
4 2026-03-11 PRIMARY DOCUMENT view ·
4 2026-03-11 PRIMARY DOCUMENT view ·
4 2026-03-11 PRIMARY DOCUMENT view ·
4 2026-03-11 PRIMARY DOCUMENT view ·
4 2026-03-11 PRIMARY DOCUMENT view ·
4 2026-03-11 PRIMARY DOCUMENT view ·
4 2026-03-11 PRIMARY DOCUMENT view ·
4 2026-03-11 PRIMARY DOCUMENT view ·
10-K 2026-03-04 10-K view ·
8-K 2026-03-04 8-K view ·
8-K 2026-02-26 8-K view ·
8-K 2026-02-02 8-K view ·
8-K 2026-01-09 8-K view ·
4 2025-12-05 PRIMARY DOCUMENT view ·
4 2025-12-04 PRIMARY DOCUMENT view ·
4 2025-11-12 PRIMARY DOCUMENT view ·
8-K 2025-11-06 8-K view ·
10-Q 2025-11-05 10-Q view ·
8-K 2025-11-05 8-K view ·
4 2025-10-17 PRIMARY DOCUMENT view ·
4 2025-10-17 PRIMARY DOCUMENT view ·
4 2025-10-17 PRIMARY DOCUMENT view ·
8-K 2025-10-08 8-K view ·
8-K 2025-10-01 8-K view ·
4 2025-09-29 PRIMARY DOCUMENT view ·
4 2025-09-29 PRIMARY DOCUMENT view ·
4 2025-09-22 PRIMARY DOCUMENT view ·
4 2025-09-08 PRIMARY DOCUMENT view ·

About AQST

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The…

Options picks · AQST

ITM + OTM ideas from the latest scan

Loading…

Congress trades · AQST

STOCK Act disclosures

Loading…

SEC filings & insiders · AQST

EDGAR · live

Loading…

Holders · AQST

Institutions & insider activity

Loading…